House bill mandates generics on Medicare formularies

A new House bill aims to cut Medicare prescription drug costs by requiring generic medications on all Part D formularies. Dubbed a mandate for generics, the measure was referred to the House Committees on Energy and Commerce and Ways and Means for review, as determined by the Speaker. This step signals growing momentum to expand affordable drug access under Medicare.[2][1]

The legislation builds on the Inflation Reduction Act of 2022, which empowered Medicare to negotiate prices for high-cost, single-source drugs without generic competition, with negotiated "maximum fair prices" set for 10 drugs starting in 2026. Medicare Part D plans must already cover these negotiated drugs on formularies, but the bill pushes further by mandating generics to drive down costs amid rising drug expenses. The Energy and Commerce Committee has advanced similar measures in recent years to promote lower prices and biosimilar access.[1][4][10]

For Milwaukee residents, this matters deeply as Wisconsin's Medicare enrollees—over 1.2 million statewide—face some of the nation's highest Part D premiums. Cheaper generics could save seniors thousands on everyday medications like blood pressure or diabetes drugs, easing fixed-income budgets in a city where 15% of adults are Medicare-eligible. Local pharmacies and clinics serving Milwaukee's aging population stand to benefit from stabilized supply chains.[1][7]

Next, the committees will debate and amend the bill before a full House vote, potentially aligning it with ongoing CMS efforts for 2026 formularies. Passage could fast-track implementation by next year.[2]